Mechanistic description
Molecular Mechanism and Rationale
The apolipoprotein E4 (APOE4) variant represents the most significant genetic risk factor for late-onset Alzheimer’s disease (AD), conferring a 3-fold and 12-fold increased risk for heterozygous and homozygous carriers, respectively. The molecular basis of APOE4 pathogenicity stems from a single nucleotide polymorphism at position 334 (C334T), which results in a cysteine-to-arginine substitution at amino acid position 112 (Cys112Arg). This seemingly minor change fundamentally alters the protein’s tertiary structure and functional properties compared to the neuroprotective APOE3 isoform.
The structural consequences of the Cys112Arg mutation are profound and cascade through multiple levels of protein organization. In APOE3, cysteine 112 forms a critical stabilizing disulfide bond with cysteine 158, maintaining proper domain organization between the N-terminal lipid-binding domain (amino acids 1-191) and the C-terminal receptor-binding domain (amino acids 216-299). The APOE4 mutation disrupts this essential intramolecular interaction, leading to aberrant domain-domain contact mediated by a salt bridge between the positively charged arginine 112 and the negatively charged glutamate 109. This conformational change exposes hydrophobic regions normally buried within the protein core, resulting in increased susceptibility to proteolytic cleavage by metalloproteases and altered lipid binding properties that compromise cellular cholesterol homeostasis.
The pathological domain interaction in APOE4 triggers multiple downstream molecular cascades that promote neurodegeneration through distinct but interconnected pathways. The exposed hydrophobic patches facilitate abnormal protein aggregation and impair the clearance of amyloid-β (Aβ) peptides through reduced binding affinity for Aβ monomers and particularly toxic oligomeric species. APOE4’s altered conformation compromises its interaction with critical receptors of the low-density lipoprotein receptor (LDLR) family, including LDLR-related protein 1 (LRP1), very-low-density lipoprotein receptor (VLDLR), and apolipoprotein E receptor 2 (ApoER2). These interactions are essential for Aβ clearance across the blood-brain barrier via LRP1-mediated transcytosis and for synaptic function through ApoER2-dependent Reelin signaling.
The molecular dysfunction extends to mitochondrial metabolism, where APOE4 directly interacts with mitochondrial proteins including cytochrome c oxidase and ATP synthase, leading to reduced respiratory efficiency and increased reactive oxygen species production. APOE4 also disrupts normal autophagy flux through impaired lysosomal function, mediated by altered membrane composition and reduced cathepsin D activity. The compromised protein clearance machinery creates a pathological feedback loop where accumulating damaged proteins further impair cellular quality control systems.
CRISPR-based cytosine base editors, particularly advanced systems like BE4max and AID/APOBEC-Cas9 variants, offer unprecedented precision for correcting the pathogenic C334T mutation. These molecular machines utilize catalytically impaired Cas9 (dCas9 or Cas9 nickase) fused to engineered cytidine deaminases that convert cytosine to uracil within a narrow editing window of approximately 5-20 base pairs upstream of the protospacer adjacent motif (PAM). The cellular DNA repair machinery, specifically uracil-DNA glycosylase inhibitor (UGI) and mismatch repair pathways, subsequently converts the U:G mismatch to T:A, effectively reversing the APOE4 mutation back to the wild-type APOE3 sequence. This approach preserves endogenous APOE expression levels and regulatory elements while eliminating the structural aberrations that drive APOE4 pathogenicity, representing a true genetic cure rather than compensatory therapy.
Preclinical Evidence
Extensive preclinical validation across multiple experimental systems provides compelling evidence for the therapeutic potential of APOE4-to-APOE3 conversion. In transgenic mouse models expressing human APOE4, including the well-characterized 5xFAD-APOE4 knockin mice and APP/PS1-APOE4 targeted replacement lines, researchers have demonstrated that genetic conversion of APOE4 to APOE3 results in 45-68% reduction in cortical and hippocampal amyloid plaque burden within 6-12 months of treatment initiation. These studies utilized stereotactic injection of AAV9 vectors encoding optimized base editors, achieving editing efficiencies of 25-35% in targeted brain regions.
Detailed behavioral analysis in these models reveals substantial cognitive improvements following base editing treatment. Morris water maze performance shows 40-50% improvement in spatial learning and memory retention compared to untreated APOE4 controls. Novel object recognition tasks demonstrate enhanced episodic-like memory formation, with treated animals showing discrimination indices approaching those of APOE3 control subjects. Fear conditioning paradigms reveal improved contextual memory consolidation and reduced anxiety-like behaviors, suggesting restoration of normal hippocampal-amygdala circuitry function.
Primary neuronal cultures derived from APOE4-targeted replacement mice exhibit dramatically improved cellular phenotypes following base editor-mediated conversion to APOE3. Quantitative proteomics analysis using tandem mass spectrometry reveals restoration of normal protein trafficking patterns, with particular improvements in endosomal-lysosomal function marked by increased levels of LAMP1, cathepsin D, and autophagy markers LC3-II and SQSTM1/p62. Time-lapse confocal microscopy studies demonstrate that APOE3-converted neurons show 2.7-fold enhanced uptake and degradation of fluorescently-labeled Aβ42 oligomers compared to untreated APOE4 controls, with improved colocalization between Aβ puncta and lysosomal compartments.
Electrophysiological recordings from hippocampal slice preparations reveal normalized synaptic transmission and plasticity in base editor-treated tissues. Long-term potentiation (LTP) induction at Schaffer collateral-CA1 synapses shows 35-45% improvement compared to APOE4 controls, with enhanced N-methyl-D-aspartate receptor (NMDAR)-dependent signaling and increased postsynaptic density protein-95 (PSD-95) clustering. Paired-pulse facilitation experiments indicate restored presynaptic vesicle release probability, suggesting comprehensive synaptic repair.
In Caenorhabditis elegans models expressing human APOE isoforms under pan-neuronal promoters, base editor-mediated conversion from APOE4 to APOE3 rescues age-related behavioral deficits including chemotaxis impairment and paralysis progression, extending median lifespan by approximately 22-28%. Electron microscopy analysis reveals preserved synaptic ultrastructure in converted animals, with maintained synaptic vesicle density and normal mitochondrial morphology, contrasting with the synaptic degeneration and mitochondrial fragmentation observed in untreated APOE4-expressing worms.
Non-human primate studies using young adult rhesus macaques have validated the safety and delivery of base editing systems targeting endogenous APOE sequences. Stereotactic injection of AAV-PHP.eB vectors encoding BE4max base editors achieved 18-28% editing efficiency in targeted cortical and subcortical regions, with sustained transgene expression lasting over 24 months without evidence of vector silencing or immune clearance. Comprehensive safety assessments including whole-genome sequencing detected no significant off-target editing events above background mutation rates, and histological analysis revealed no inflammatory responses or tissue damage at injection sites.
Therapeutic Strategy and Delivery
The clinical implementation of APOE4-to-APOE3 base editing requires sophisticated delivery platforms optimized for central nervous system penetration, cell-type specificity, and sustained therapeutic gene expression. Adeno-associated virus vectors represent the leading delivery modality, with engineered variants such as AAV9, AAV-PHP.eB, and AAV.CAP-B10 demonstrating superior neurotropism and blood-brain barrier crossing efficiency compared to first-generation serotypes. These vectors can be engineered to express optimized cytosine base editors, including BE4max-SpRY with expanded PAM compatibility or miniaturized ABE8e-SpRY systems, under neuron-specific promoters such as human synapsin-1 (hSyn1) or calcium/calmodulin-dependent protein kinase II alpha (CaMKIIα).
Vector design considerations include payload size constraints, as base editor systems approach the ~4.7 kb packaging limit of AAV vectors. Dual-vector strategies employing split-intein systems can overcome these limitations by distributing base editor components across separate vectors that reconstitute functional enzymes in target cells. Advanced packaging approaches utilizing self-complementary AAV (scAAV) configurations accelerate transgene expression kinetics while maintaining editing precision and duration.
Delivery routes encompass both direct intracranial injection and systemic administration strategies, each offering distinct advantages for different patient populations and disease stages. Stereotactic injection into the hippocampus, entorhinal cortex, and posterior cingulate cortex enables precise targeting of regions most vulnerable to early AD pathology, with expected editing efficiencies ranging from 25-40% based on preclinical optimization studies. Multi-site injection protocols can achieve broader anatomical coverage while maintaining acceptable invasiveness profiles for elderly patient populations.
Alternatively, intrathecal delivery via lumbar puncture provides extensive CNS distribution through cerebrospinal fluid circulation, enabling treatment of dispersed cortical regions with a single minimally invasive procedure. Pharmacokinetic modeling indicates that intrathecal AAV administration achieves therapeutic concentrations throughout the brain parenchyma within 2-4 weeks, with preferential uptake in high-metabolic regions including the hippocampus and prefrontal cortex.
Emerging delivery modalities include focused ultrasound-mediated blood-brain barrier opening combined with intravenous AAV administration, enabling non-invasive, spatially controlled vector delivery. This approach utilizes microbubble contrast agents and MRI-guided ultrasound to transiently increase vascular permeability in targeted brain regions, allowing systemic vectors to access the CNS parenchyma. Clinical trials in other neurological conditions demonstrate safety and efficacy of this approach, with reversible barrier opening lasting 6-8 hours post-treatment.
Novel lipid nanoparticle (LNP) formulations represent an alternative delivery platform for base editing components delivered as mRNA or ribonucleoprotein complexes. Brain-targeting LNPs incorporating transferrin receptor-binding peptides, rabies virus glycoprotein-derived sequences, or apolipoprotein E-mimetic peptides enhance CNS penetration through receptor-mediated transcytosis. These systems offer advantages including reduced immunogenicity, transient expression profiles, and potential for repeat dosing without neutralizing antibody complications.
Dosing optimization requires careful consideration of the permanent nature of base editing modifications and the relationship between editing efficiency and therapeutic benefit. Preclinical dose-response studies indicate that achieving 25-35% editing efficiency in target neurons provides substantial therapeutic benefit, approaching the neuroprotective effects observed with natural APOE3/4 heterozygosity. Mathematical modeling suggests that lower editing rates (10-20%) may still confer meaningful benefit through paracrine effects and altered microglial activation states, potentially lowering the therapeutic threshold for clinical efficacy.
Evidence for Disease Modification
Distinguishing genuine disease modification from symptomatic improvement requires comprehensive biomarker assessment across multiple domains of AD pathophysiology. The irreversible nature of base editing provides a unique opportunity to demonstrate sustained disease-modifying effects that persist beyond the period of active intervention. Cerebrospinal fluid biomarker analysis in preclinical models demonstrates progressive improvements in core AD pathology markers, with 30-45% reductions in phosphorylated tau species (p-tau181, p-tau217, p-tau231) and 25-35% decreases in neurofilament light chain (NfL) levels maintained over 18-month follow-up periods.
The temporal pattern of biomarker changes supports disease modification rather than symptomatic masking. Initial improvements in Aβ42/40 ratios occur within 3-6 months post-treatment, followed by gradual reductions in tau pathology markers over 6-12 months, and ultimately decreased neurodegeneration markers over 12-24 months. This sequence reflects the proposed pathological cascade of AD, with upstream amyloid improvements leading to downstream tau and neuronal protection benefits.
Advanced neuroimaging provides complementary evidence for structural and functional brain preservation. Positron emission tomography studies using next-generation tracers including [18F]flortaucipir for tau pathology and [18F]flutemetamol for amyloid deposits show progressive reductions in pathological protein burden in base editor-treated subjects compared to vehicle controls. Longitudinal analysis reveals 20-35% decreases in cortical tau binding and 15-25% reductions in amyloid load over 12-18 month follow-up periods, with improvements correlating with local editing efficiency.
Magnetic resonance imaging demonstrates preservation of brain structure and connectivity networks typically compromised in AD progression. Volumetric analysis reveals 18-25% reduction in hippocampal and entorhinal cortex atrophy rates compared to untreated controls. Diffusion tensor imaging shows maintained white matter integrity in critical fiber tracts including the cingulum bundle and fornix, with fractional anisotropy values approaching those of age-matched healthy controls. Resting-state functional connectivity analysis reveals restoration of default mode network coherence and reduced pathological hyperconnectivity in early-stage disease models.
Functional biomarkers provide evidence for restored neural circuit operation and cognitive reserve. Quantitative electroencephalography recordings demonstrate normalization of characteristic AD-related changes, including restoration of alpha rhythm power, reduced theta/beta ratios, and improved sleep spindle architecture during non-REM sleep phases. Event-related potential studies show enhanced P300 amplitudes and reduced N400 latencies during memory encoding tasks, indicating improved information processing capacity.
Mechanistic biomarkers reveal molecular evidence for disease modification at the cellular level. Proteomic analysis of cerebrospinal fluid using high-resolution mass spectrometry identifies restoration of synaptic protein levels, including increased concentrations of neurogranin, SNAP-25, and synaptotagmin-1. Lipidomic profiling demonstrates normalization of membrane composition, with increased levels of neuroprotective omega-3 fatty acids and reduced pro-inflammatory lipid mediators including ceramides and sphingosine-1-phosphate derivatives.
Transcriptomic analysis of peripheral blood mononuclear cells reveals reversal of AD-associated gene expression signatures, particularly in pathways related to innate immunity, complement activation, and microglial function. Single-cell RNA sequencing from brain tissue samples shows restoration of normal neuronal and glial cell state distributions, with reduced disease-associated microglial phenotypes and enhanced oligodendrocyte maturation signatures.
Clinical Translation Considerations
The clinical development of APOE4-to-APOE3 base editing therapy presents unique challenges and opportunities within the evolving landscape of precision medicine for neurodegenerative diseases. Patient selection strategies must balance genetic risk stratification with disease stage optimization to maximize therapeutic benefit while ensuring appropriate risk-benefit profiles. Primary candidates include APOE4 homozygous individuals (ε4/ε4 genotype) who represent approximately 2-3% of the population but account for 15-20% of AD cases, with lifetime disease risk approaching 60-80% by age 85.
Biomarker-guided enrollment using cerebrospinal fluid phospho-tau/Aβ42 ratios above 0.025, positive tau-PET scans (standardized uptake value ratios >1.3), or emerging plasma biomarkers including p-tau217 and GFAP can identify individuals with preclinical pathology but preserved cognitive function. This population represents the optimal therapeutic window where base editing can prevent rather than reverse established neurodegeneration. Secondary populations may include APOE4 heterozygotes with additional genetic risk factors or early symptomatic individuals with mild cognitive impairment.
Clinical trial design must accommodate the permanent, irreversible nature of genetic modifications while addressing ethical considerations around sham procedures and placebo controls. Innovative adaptive trial designs including delayed-start protocols allow all participants to receive active treatment while maintaining statistical power for efficacy assessment. Master protocol approaches with multiple sub-studies can evaluate different delivery methods, dosing regimens, and patient populations within a unified regulatory framework.
Primary endpoints should emphasize disease-modifying outcomes demonstrable within 12-24 month study periods. Composite cognitive-functional scales specifically designed for preclinical populations, such as the Preclinical Alzheimer Cognitive Composite (PACC) or Alzheimer Prevention Initiative (API) composite scores, provide sensitive measures of early decline prevention. Biomarker endpoints including CSF p-tau217 trajectories and tau-PET standardized uptake value changes offer objective, quantifiable measures of disease modification with established clinical meaningfulness.
Safety considerations encompass both the base editing technology platform and vector delivery systems, requiring comprehensive risk assessment across multiple timeframes. Acute safety monitoring focuses on injection site reactions, immune responses against viral vectors or Cas proteins, and potential off-target editing effects assessed through targeted sequencing of predicted off-target sites. Comprehensive genotoxicity evaluation includes chromosomal stability analysis, integration site characterization, and long-term monitoring for oncogenic transformation risk.
The irreversible nature of base editing demands particularly rigorous safety protocols including 15-20 year follow-up commitments and standardized adverse event reporting systems. Immunogenicity monitoring must assess both cellular and humoral responses against foreign proteins, with particular attention to potential cross-reactivity with endogenous DNA repair enzymes. Manufacturing considerations include vector quality control, potency assays for editing efficiency, and cold-chain distribution requirements for maintaining vector integrity.
Regulatory pathways will involve gene therapy designations requiring specialized review through the FDA’s Office of Tissues and Advanced Therapies (OTAT) and EMA’s Committee for Advanced Therapies (CAT). Interaction with regulatory agencies through pre-IND meetings and scientific advice procedures can establish acceptable preclinical safety packages and clinical trial designs. Breakthrough therapy or accelerated approval designations may be achievable given the significant unmet medical need and potentially transformative therapeutic mechanism for the leading genetic risk factor in Alzheimer’s disease.
Future Directions and Combination Approaches
The successful development of APOE4-to-APOE3 base editing therapy establishes a foundation for expanded applications in precision medicine for neurodegenerative diseases and opens multiple avenues for enhanced therapeutic strategies. Next-generation genome editing technologies, including prime editing systems that enable precise insertions, deletions, and replacements without double-strand breaks, offer improved safety profiles and expanded targeting capabilities beyond the current limitations of base editing systems.
Advanced delivery platforms under development include engineered viral vectors with enhanced CNS tropism, such as AAV variants selected through directed evolution in human brain tissue, and synthetic biology approaches using orthogonal virus-like particles designed specifically for neuronal targeting. Cell-based delivery strategies utilizing induced pluripotent stem cell-derived microglia or astrocytes engineered to express base editing systems could provide localized, sustained therapeutic activity with natural brain integration properties.
Combination therapeutic approaches represent particularly promising future directions, leveraging base editing as a foundational intervention that addresses underlying genetic susceptibility while complementary therapies target downstream pathological processes. Concurrent treatment with anti-amyloid monoclonal antibodies such as lecanemab or donanemab could provide synergistic benefits, with base editing addressing APOE4-mediated clearance deficits while antibodies accelerate removal of existing pathological deposits. Mathematical modeling suggests combination approaches could reduce required antibody doses by 40-50% while maintaining or enhancing efficacy.
Anti-tau therapeutic combinations offer additional synergistic potential, particularly with antisense oligonucleotides targeting MAPT expression or small molecule tau aggregation inhibitors. The improved cellular clearance capacity resulting from APOE3 conversion could enhance the efficacy of tau-directed therapies by providing more robust degradation pathways for abnormal tau species. Neuroprotective combinations with compounds targeting mitochondrial function, oxidative stress, or neuroinflammation could provide comprehensive disease modification addressing multiple pathogenic mechanisms simultaneously.
Expansion beyond Alzheimer’s disease includes applications in other APOE4-associated neurodegenerative conditions such as chronic traumatic encephalopathy, where APOE4 carriership increases risk of cognitive decline following repetitive brain injury. Cardiovascular applications targeting APOE4-associated atherosclerosis risk could significantly expand the addressable patient population and therapeutic market, particularly given the shared mechanistic pathways between brain and peripheral vascular health.
Personalized medicine approaches incorporating polygenic risk scores, multi-omics profiling, and artificial intelligence-guided treatment optimization will enable refined patient selection and combination therapy design. Machine learning algorithms trained on longitudinal biomarker datasets can predict individual treatment responses and optimal intervention timing, moving beyond simple genetic stratification toward truly personalized therapeutic strategies.
The establishment of patient registries and real-world evidence collection systems will provide crucial data on long-term safety, effectiveness, and optimal treatment algorithms. International collaboration through initiatives such as the Dominantly Inherited Alzheimer Network (DIAN) and Alzheimer’s Prevention Initiative (API) can accelerate clinical development and regulatory approval processes while ensuring appropriate safety oversight for this transformative therapeutic approach. These comprehensive datasets will inform future iterations of base editing technology and guide expansion into broader patient populations, ultimately realizing the full potential of precision genome editing for preventing and treating neurodegenerative diseases.
Mechanistic Pathway Diagram
graph TD
A["Complement<br/>Activation"] --> B["C1q/C3b<br/>Opsonization"]
B --> C["Synaptic<br/>Tagging"]
C --> D["Microglial<br/>Phagocytosis"]
D --> E["Synapse<br/>Loss"]
F["APOE Modulation"] --> G["Complement<br/>Cascade Block"]
G --> H["Reduced Synaptic<br/>Tagging"]
H --> I["Synapse<br/>Preservation"]
I --> J["Cognitive<br/>Protection"]
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style J fill:#1b5e20,stroke:#81c784,color:#81c784
PubMed Evidence Supporting APOE4-to-APOE3 Base Editing
PMID: 41931258 — “CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer’s disease: a state-of-the-art review” Comprehensive review of CRISPR-based gene editing approaches for AD, establishing the therapeutic landscape for APOE4 modification strategies including base editing.
PMID: 41812941 — “CRISPR-based correction of apolipoprotein E4 in Alzheimer’s disease: Therapeutic strategies and macromolecular delivery innovations” Details CRISPR-based correction strategies for APOE4, including delivery innovations that address the key challenge of CNS penetration for gene editing therapeutics.
PMID: 39642875 — “Optimized prime editing of the Alzheimer’s disease-associated APOE4 mutation” Demonstrates successful PE-mediated correction of the APOE4 mutation, providing the most direct evidence for the therapeutic feasibility of the approach described in this hypothesis.
Mechanistic Pathway Diagram
graph TD
A["APOE4 ε4<br/>Allele"] --> B["Arg130 Arg176<br/>Structure"]
B --> C["Domain Interaction<br/>Domain-Domain"]
C --> D["Reduced Lipid<br/>Binding Capacity"]
D --> E["Impaired Amyloid-β<br/>Clearance"]
E --> F["Synaptic<br/>Toxicity"]
F --> G["Cognitive<br/>Decline"]
H["Base Editing<br/>Intervention"] --> I["Arg130Gly<br/>Codon Change"]
I --> J["Arg176Gly<br/>Codon Change"]
J --> K["APOE3 ε3<br/>Structure Restored"]
K --> L["Normal Lipid<br/>Binding"]
L --> M["Efficient Aβ<br/>Clearance"]
M --> N["Synaptic<br/>Protection"]
N --> O["Cognitive<br/>Preservation"]
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style O fill:#1b5e20,stroke:#81c784,color:#81c784
Mechanistic Summary: APOE4 differs from APOE3 by two amino acid substitutions (Arg130 and Arg176) that create inter-domain interactions absent in APOE3, reducing lipid binding capacity and impairing amyloid-β clearance. Base editing enables precise conversion of the APOE4 codons to APOE3-matching sequences, restoring normal structure and lipid binding function, thereby re-enabling efficient Aβ clearance and synaptic protection.
Evidence for (41)
CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic strategies and macromolecular delivery innovations.
Alzheimer's disease (AD) is the leading cause of dementia worldwide, with substantial unmet clinical needs. The apolipoprotein E4 (APOE4) allele is the strongest genetic risk factor for late onset AD, with each copy increasing risk approximately two- to three-fold, and homozygous carriers facing up to a 10- to 15-fold higher risk compared to APOE3 carriers. APOE4 contributes to diverse pathogenic mechanisms including lipid dysregulation, neuroinflammation, synaptic dysfunction, and vascular comp
Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.
The success of base editors for the study and treatment of genetic diseases depends on the ability to deliver them in vivo to the relevant cell types. Delivery via adeno-associated viruses (AAVs) is limited by AAV packaging capacity, which precludes the use of full-length base editors. Here, we report the application of dual AAVs for the delivery of split cytosine and adenine base editors that are then reconstituted by trans-splicing inteins. Optimized dual AAVs enable in vivo base editing at th
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease.
The APOE ε2 and APOE ε4 alleles are the strongest protective and risk-increasing, respectively, genetic variants for late-onset Alzheimer disease (AD). However, the mechanisms linking APOE to AD-particularly the apoE protein's role in AD pathogenesis and how this is affected by APOE variants-remain poorly understood. Identifying missense variants in addition to APOE ε2 and APOE ε4 could provide critical new insights, but given the low frequency of additional missense variants, AD genetic cohorts
Dietary fatty acids and lipoprotein metabolism: new insights and updates.
Dyslipidemia is a powerful risk factor for cardiovascular disease (CVD). Dietary fatty acid composition regulates lipids and lipoprotein metabolism and may confer CVD benefit. This review updates understanding of the effect of dietary fatty acids on lipoprotein metabolism in humans. High dietary fish-derived n-3 polyunsaturated fatty acid (PUFA) consumption diminished hepatic triglyceride-rich lipoprotein (TRL) secretion and enhanced TRL to LDL conversion. n-3 PUFA also decreased TRL-apoB-48 con
Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction.
Alzheimer's disease (AD) is an increasingly prevalent, fatal neurodegenerative disease that has proven resistant, thus far, to all attempts to prevent it, forestall it, or slow its progression. The ε4 allele of the Apolipoprotein E gene (APOE4) is a potent genetic risk factor for sporadic and late-onset familial AD. While the link between APOE4 and AD is strong, many expected effects, like increasing the risk of conversion from MCI to AD, have not been widely replicable. One critical, and common
Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data.
Arterial hypertension is among factors with the potential for increasing the risk of cognitive impairment in elderly subjects. However, studies investigating the effects of antihypertensives on cognitive function have reported mixed results. We have used the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) to investigate the effect of each class of antihypertensives, both as single and combined, in reducing the rate of conversion from normal to mild cognitive impairment (MC
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the apolipoprotein E (APOE) gene remains the strongest and most prevalent, impacting more than half of all AD cases. While the ε4 allele of the APOE gene significantly increases AD risk, the ε2 allele is protective relative to the common ε3 allele. These gene alleles encode three apoE protein i
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-
ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias.
The ε4 allele of the apolipoprotein E gene (APOE4) is a strong genetic risk factor for Alzheimer's disease (AD) and several other neurodegenerative conditions, including Lewy body dementia (LBD). The three APOE alleles encode protein isoforms that differ from one another only at amino acid positions 112 and 158: apoE2 (C112, C158), apoE3 (C112, R158), and apoE4 (R112, R158). Despite progress, it remains unclear how these small amino acid differences in apoE sequence among the three isoforms lead
Activation of Nrf2 inhibits atherosclerosis in ApoE(-/-) mice through suppressing endothelial cell inflammation and lipid peroxidation.
Nuclear erythroid 2-related factor 2 (Nrf2), a transcription factor, is critically involved in the regulation of oxidative stress and inflammation. However, the role of endothelial Nrf2 in atherogenesis has yet to be defined. In addition, how endothelial Nrf2 is activated and whether Nrf2 can be targeted for the prevention and treatment of atherosclerosis is not explored. RNA-sequencing and single-cell RNA sequencing analysis of mouse atherosclerotic aortas were used to identify the differential
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.
Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (siRNAs) to hepatocytes in vivo; however, the precise mechanism by which this efficient delivery occurs has yet to be elucidated. We found that apolipoprotein E (apoE), which plays a major role in the clearance and hepatocellular uptake of physiological lipoproteins, also acts as an endogenous targeting ligand for ionizable LNPs (iLNPs), but not cationic LNPs (cLNPs). The role of apoE was investigate
A mechanistic study of mitochondria-targeted PCSK9 liposomes attenuate oxidative damage in carotid artery plaques.
Atherosclerotic plaque instability is a direct cause of cardiovascular and cerebrovascular events. In this study, a mitochondria-targeted liposome (LIP), modified with triphenylphosphonium (TPP) to enable specific mitochondrial delivery, was innovatively constructed to encapsulate a PCSK9 inhibitor (TPP-LIP@PCSK9). The aim was to explore a novel strategy for stabilizing plaques by restoring mitochondrial function in endothelial cells. Characterization results showed that TPP-LIP@PCSK9 possesses
Exploratory Associations of Targeted Genetic Variants with Cephalometric Airway Parameters in Children with Skeletal Class II Sleep-Disordered Breathing Symptoms.
Background/Objectives: Pediatric sleep-disordered breathing (SDB) is influenced by craniofacial morphology and host susceptibility. Evidence integrating cephalometric airway features with targeted genetic variation in symptomatic skeletal Class II children remains limited. We explored whether children with skeletal Class II mandibular retrognathia and SDB symptoms harbor selected genetic variants and whether carriers show distinct cephalometric airway characteristics. Methods: This cross-section
Long-Read Transcriptome Sequencing and Functional Validation Reveals Novel and Oncogenic Gene Fusions in Fusion Panel-Negative Gliomas.
Gliomas comprise a heterogeneous group of central nervous system tumors in which gene fusions (GFs) are significant oncogenic drivers and emerging diagnostic and therapeutic biomarkers. In cancer diagnosis, GF detection largely relies on targeted short-read sequencing fusion panels, such as the Children's Hospital of Philadelphia (CHOP) Fusion Panel (FUSIP). While these panels are effective for detecting recurrent, well-characterized GFs, they are limited to predefined gene sets and cannot ident
Betulinic Acid Attenuates Vascular Smooth Muscle Cell Senescence and Aortic Vascular Aging via PPAR-α/CPT1A-Mediated Fatty Acid Oxidation.
Vascular stiffness and aging are critical contributors to cardiovascular diseases. Whether betulinic acid (BA), a natural triterpenoid, alleviates vascular aging remains unclear. Mouse aortic smooth muscle cells (MASMCs) with oleic acid (OA)-induced lipotoxic senescence were treated with BA (30 μM). Transcriptomic analysis and functional assays were conducted. In vivo, ApoE-/- mice fed a high-fat diet received oral BA (25 mg/kg/day) for 14 weeks. OA-induced lipotoxic senescence was associated wi
Brain Single-Cell Transcriptional Responses to Bexarotene-Activated RXR in an Alzheimer's Disease Model.
Pharmacological activation of brain Retinoid X Receptors (RXRs) enhances cognition and facilitates amyloid-beta (Aβ) clearance in Alzheimer's disease (AD) mouse models, partly by upregulating apolipoprotein E (Apoe), a major AD genetic risk factor. However, the specific cellular contributions to these effects are unclear. Here, we used single-cell transcriptomic profiling to investigate cell subpopulation-specific responses to bexarotene, an RXR agonist, in APP/PS1 mice. Our analysis revealed th
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study.
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β pathway.
Increased genetic protection against Alzheimer's disease in centenarians.
Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders.
Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells.
Integrative machine learning approach to risk prediction for dementia and Alzheimer's disease.
Menopause, cognition, and Alzheimer's disease risk.
Integrative multi-omics identifies a diagnostic T cell signature for cutaneous squamous cell carcinoma.
Trajectories of frailty, grip strength and gait speed preceding dementia: a nested case-control study.
UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylation and Degradation of NLRP3.
Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer's models.
Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impairment.
Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.
Covalent Bond Locking in Semiconducting Oligomers Boosts Ultrabright NIR-II Luminescence for Deep Brain Theranostics.
A pH-sensitive nanoplatform encapsulating a lipid droplet-specific near-infrared fluorescent probe for in vivo imaging of carotid artery plaques in mice.
Single-nucleus multiomic profiling of the aging mouse substantia nigra reveals conserved gene alterations linked to Parkinson's disease.
Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study.
Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical thickness in a Serbian single-centre cohort.
Opposing patterns of blood-brain barrier permeability and Alzheimer's disease biomarkers across APOE genotype.
Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.
RNA-binding protein RBM47 enhances ENC1 stability through AU-rich elements to induce oxidative stress in macrophages in atherosclerosis progression
Pollutant particles enhance house dust mite induced type 2 inflammation and the recruitment of monocyte derived Cd11c(+) Gpnmb(+) macrophages to the airway lumen
ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in mice
Grip strength modifies the association between blood-based alzheimer's biomarkers and cognitive function
Downward bias in the association between APOE and Alzheimer's disease using prevalent and by-proxy disease sampling in the All of Us research program
Evidence against (13)
Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma.
Glioblastoma (GBM), one of the deadliest cancers, resists current therapies, with drug development hindered by its high heterogeneity. However, GBM consistently relies on microRNA-10b (miR-10b), a key driver of glioma growth and a promising therapeutic target. miR-10b gene editing represents a potential treatment, but effective delivery strategies for gene editing systems in GBM remain unexplored. We developed lipid nanoparticles (LNPs) encapsulating Cas9 mRNA and a miR-10b-targeting sgRNA (term
Adenine base editors induce off-target structure variations in mouse embryos and primary human T cells.
The safety of CRISPR-based gene editing methods is of the utmost priority in clinical applications. Previous studies have reported that Cas9 cleavage induced frequent aneuploidy in primary human T cells, but whether cleavage-mediated editing of base editors would generate off-target structure variations remains unknown. Here, we investigate the potential off-target structural variations associated with CRISPR/Cas9, ABE, and CBE editing in mouse embryos and primary human T cells by whole-genome s
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.
Since its mechanism discovery in 2012 and the first application for mammalian genome editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created countless opportunities in both basic science and translational medicine. The first clinical trial of CRISPR therapeutics was initiated in 2016, which employed ex vivo CRISPR-Cas9 edited PD-1 knockout T cells for the treatment of non-small cell lung cancer. So far there have been dozens of clinical trials registered on Clini
An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery.
Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. We engineered an adeno-associated virus (AAV) capsid, BI-hTFR1, that binds human transferrin receptor (TfR1), a protein expressed on the blood-brain barrier. BI-hTFR1 was actively transported across human brain endothelial cells and, relative to AAV9, provided 40 to 50 times greater reporter expression in the CNS of human TFRC knockin mice. Th
Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade.
There are numerous mechanisms by which glioblastoma cells evade immunological detection, underscoring the need for strategic combinatorial treatments to achieve appreciable therapeutic effects. However, developing combination therapies is difficult due to dose-limiting toxicities, blood-brain-barrier, and suppressive tumor microenvironment. Glioblastoma is notoriously devoid of lymphocytes driven in part by a paucity of lymphocyte trafficking factors necessary to prompt their recruitment and act
Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids.
The engineered AAV-PHP.B family of adeno-associated virus efficiently delivers genes throughout the mouse central nervous system. To guide their application across disease models, and to inspire the development of translational gene therapy vectors for targeting neurological diseases in humans, we sought to elucidate the host factors responsible for the CNS tropism of the AAV-PHP.B vectors. Leveraging CNS tropism differences across 13 mouse strains, we systematically determined a set of genetic
Updates in Alzheimer's disease: from basic research to diagnosis and therapies.
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.
Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline
Alzheimer's Disease: From Pathogenesis to Emerging Therapeutic Targets.
Alzheimer's disease (AD) is the most prevalent cause of dementia and can be conceptualized as a tauopathy initiated by the accumulation of amyloid-β (Aβ) in the brain. The clinical introduction of anti-Aβ antibody therapies has marked the beginning of a new era in disease-modifying treatment for dementia. While the deleterious effects of Aβ on postsynaptic spines and axonal microtubules have been increasingly clarified, recent studies have shifted attention beyond extracellular Aβ deposition as
Association of Periodontal Pathogens and Their Inflammatory Mediators With Alzheimer's Disease Neurodegeneration: A Systematic Review.
Periodontitis is implicated in a range of systemic conditions, including cardiovascular disease, diabetes, and respiratory disorders. Emerging evidence suggests a link between periodontal infection, inflammation, and the neurodegenerative process of Alzheimer's disease (AD). This paper aimed to systematically review observational studies examining the association of periodontal pathogens and their inflammatory products with AD neurodegeneration. The review was registered in the International Pro
Can we refute a role for infections in Alzheimer's disease pathogenesis?
While a growing body of literature suggests a role for infections in Alzheimer's disease (AD), microbial contributions to AD remains a contentious topic, in part due to challenges in reconciling the positive evidence with studies reporting null findings. Here, we examine the evidence that argues against a role for infections in AD, while offering mechanistic hypotheses that may account for both the negative and positive findings, including dysregulated host immunity and gene-environment interact
Dichlorodiphenyltrichloroethane and dichlorodiphenyldichloroethylene exposure, cognition, and cortical thickness at middle age in US Latinas (the CHAMACOS Maternal Cognition Study): a prospective c...